N.V. Rajeshkumar

Gemcitabine Plus<i>nab</i>-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

Daniel D. Von Hoff, Ramesh K. Ramanathan, Mitesh J. Borad et al. · Journal of Clinical Oncology · 2011 · 1K citations · Full text

Medicine, Oncology, Pharmacology +12

Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations

Annan Yang, N.V. Rajeshkumar, Xiaoxu Wang et al. · Cancer Discovery · 2014 · 480 citations · Full text

Medicine, Oncology, Pharmacology +17

Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma

Zeshaan A. Rasheed, Jie Yang, Qiuju Wang et al. · JNCI Journal of the National Cancer Institute · 2010 · 430 citations · Full text

Medicine, Cancer Biology, Oncology +15

A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

Manuel Hidalgo, Elizabeth Bruckheimer, N.V. Rajeshkumar et al. · Molecular Cancer Therapeutics · 2011 · 402 citations · Full text

Medicine, Oncology, Pharmacology +11

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

N.V. Rajeshkumar, Elizabeth De Oliveira, Niki A. Ottenhof et al. · Clinical Cancer Research · 2011 · 279 citations · Full text

Medicine, Oncology, Pharmacology +16